List view / Grid view
The CDMO AMRI has said it will boost its production of the malaria drug hydroxychloroquine sulfate, identified as a potential COVID-19 treatment, following an emergency use authorisation from the FDA.
In light of the COVID-19 pandemic, WHO has asked the pharmaceutical supply chain to swiftly distribute nets and antimalarial medicines in sub-Saharan Africa.
It appears the world was unprepared for a novel coronavirus, despite historical precedents. Dave Elder provides some insight on the disease and what the pharmaceutical community is doing to tackle the pandemic.
The COVID-19 European Medicines Agency (EMA) pandemic Task Force (COVID-ETF) warned that chloroquine and hydroxychloroquine are yet to be proved effective at treating COVID-19 and that their side effects could be fatal.
India has stopped exporting the malaria drug Ipca (hydroxychloroquine), despite the FDA lifting its ban on imports due to its potential as a coronavirus treatment.
The producers of hydroxychloroquine have stated they will donate 130 million doses if the drug is approved as a treatment for the COVID-19 coronavirus.
Kenya has become the third African country to introduce the world’s first malaria vaccine into the country, in a phased pilot programme.
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
A $100 million investment has been made to support long-term vaccine manufacturing capabilities in the US.
The Government of Malawi has launched the world’s first malaria vaccine which will be made available to children up to two years of age.
The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation...
The artemisinin-based combination therapy (ACT), pyronaridine-artesunate, has been shown to be as effective in treating malaria as other drugs...
Novartis is to invest more than $ 100 million to advance research and development of new antimalarials over the next five years...
Scientists in California have undertaken studies that have demonstrated the effectiveness of a sophisticated algorithm in preventing the spread of infectious diseases. The application of AI allows authorities to identify the best use of resources and highlight subtle interaction points that might otherwise be missed.
Researchers have shown that two different compounds can safely and effectively be added to treatment regimens to block the transmission of the most common form of malaria...
